- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00095082
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
January 26, 2017 updated by: Novo Nordisk A/S
Efficacy and Safety Comparison of Insulin Detemir Plus Insulin Aspart Versus Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe and the United States of America (USA).
The purpose of this study is to test whether insulin detemir is a safe and at least as effective alternative to insulin glargine for the control of blood glucose in basal/bolus therapy in patients with type I diabetes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
447
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Helsinki, Finland, 00250
- Novo Nordisk Investigational Site
-
Kuopio, Finland, 70210
- Novo Nordisk Investigational Site
-
Oulu, Finland, 90029
- Novo Nordisk Investigational Site
-
Pori, Finland, 28500
- Novo Nordisk Investigational Site
-
Vantaa, Finland, 01400
- Novo Nordisk Investigational Site
-
-
-
-
-
ANGERS cedex 09, France, 49033
- Novo Nordisk Investigational Site
-
Antibes, France, 06600
- Novo Nordisk Investigational Site
-
Brest, France, 29609
- Novo Nordisk Investigational Site
-
GRENOBLE cedex, France, 38043
- Novo Nordisk Investigational Site
-
LA ROCHELLE cedex, France, 17019
- Novo Nordisk Investigational Site
-
Mougins, France, 06250
- Novo Nordisk Investigational Site
-
TOULOUSE cedex, France, 31054
- Novo Nordisk Investigational Site
-
-
-
-
-
Alsdorf, Germany, 52477
- Novo Nordisk Investigational Site
-
Bad Kreuznach, Germany, 55545
- Novo Nordisk Investigational Site
-
Dormagen, Germany, 41539
- Novo Nordisk Investigational Site
-
Dresden, Germany, 01307
- Novo Nordisk Investigational Site
-
Flensburg, Germany, 24939
- Novo Nordisk Investigational Site
-
Friedrichsthal, Germany, 66299
- Novo Nordisk Investigational Site
-
Genthin, Germany, 39307
- Novo Nordisk Investigational Site
-
Hamburg, Germany, 20251
- Novo Nordisk Investigational Site
-
Hamburg, Germany, 22607
- Novo Nordisk Investigational Site
-
Hamburg, Germany, 21073
- Novo Nordisk Investigational Site
-
Herrenberg, Germany, 71083
- Novo Nordisk Investigational Site
-
Kippenheim, Germany, 77971
- Novo Nordisk Investigational Site
-
Rehlingen-Siersburg, Germany, 66780
- Novo Nordisk Investigational Site
-
Speyer, Germany, 67346
- Novo Nordisk Investigational Site
-
St. Ingbert, Germany, 66386
- Novo Nordisk Investigational Site
-
Völklingen, Germany, 66333
- Novo Nordisk Investigational Site
-
Würzburg, Germany, 97072
- Novo Nordisk Investigational Site
-
-
-
-
-
Almere, Netherlands, 1315 RA
- Novo Nordisk Investigational Site
-
Apeldoorn, Netherlands, 7334 DZ
- Novo Nordisk Investigational Site
-
Capelle a/d IJssel, Netherlands, 2906 ZC
- Novo Nordisk Investigational Site
-
Dordrecht, Netherlands, 3318 AT
- Novo Nordisk Investigational Site
-
Leeuwarden, Netherlands, 8934 AD
- Novo Nordisk Investigational Site
-
Zoetermeer, Netherlands, 2725 NA
- Novo Nordisk Investigational Site
-
-
-
-
-
Norrköping, Sweden, 601 82
- Novo Nordisk Investigational Site
-
Stockholm, Sweden, 112 81
- Novo Nordisk Investigational Site
-
Stockholm, Sweden, 182 88
- Novo Nordisk Investigational Site
-
Umeå, Sweden, 901 85
- Novo Nordisk Investigational Site
-
Växjö, Sweden, 351 85
- Novo Nordisk Investigational Site
-
Örebro, Sweden, 701 85
- Novo Nordisk Investigational Site
-
-
-
-
-
Abergavenny, United Kingdom, NP7 7EG
- Novo Nordisk Investigational Site
-
Ayr, United Kingdom, KA6 6DX
- Novo Nordisk Investigational Site
-
Brighton, United Kingdom, BN2 5BE
- Novo Nordisk Investigational Site
-
Bristol, United Kingdom, BS10 5NB
- Novo Nordisk Investigational Site
-
Cosham, United Kingdom, PO6 3LY
- Novo Nordisk Investigational Site
-
Dundee, United Kingdom, DD1 9SY
- Novo Nordisk Investigational Site
-
Glasgow, United Kingdom, G4 0SF
- Novo Nordisk Investigational Site
-
Livingstone, United Kingdom, EH54 6PP
- Novo Nordisk Investigational Site
-
Plymouth, United Kingdom, PL8 8DQ
- Novo Nordisk Investigational Site
-
Sheffield, United Kingdom, S5 7AU
- Novo Nordisk Investigational Site
-
Watford, United Kingdom, WD18 0HB
- Novo Nordisk Investigational Site
-
Wirral, Merseyside, United Kingdom, CH63 4JY
- Novo Nordisk Investigational Site
-
-
-
-
California
-
Anaheim, California, United States, 92801
- Novo Nordisk Investigational Site
-
Huntington Beach, California, United States, 92646
- Novo Nordisk Investigational Site
-
Inglewood, California, United States, 90301
- Novo Nordisk Investigational Site
-
Irvine, California, United States, 92618
- Novo Nordisk Investigational Site
-
La Jolla, California, United States, 92037
- Novo Nordisk Investigational Site
-
-
Florida
-
Hollywood, Florida, United States, 33021
- Novo Nordisk Investigational Site
-
Jacksonville, Florida, United States, 32216
- Novo Nordisk Investigational Site
-
Lake Mary, Florida, United States, 32746
- Novo Nordisk Investigational Site
-
Melbourne, Florida, United States, 32901
- Novo Nordisk Investigational Site
-
Tampa, Florida, United States, 33613
- Novo Nordisk Investigational Site
-
Vero Beach, Florida, United States, 32960
- Novo Nordisk Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Novo Nordisk Investigational Site
-
-
Idaho
-
Idaho Falls, Idaho, United States, 83404-7596
- Novo Nordisk Investigational Site
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Novo Nordisk Investigational Site
-
-
Kansas
-
Topeka, Kansas, United States, 66606
- Novo Nordisk Investigational Site
-
-
Maryland
-
Hyattsville, Maryland, United States, 20782
- Novo Nordisk Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States, 48235
- Novo Nordisk Investigational Site
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Novo Nordisk Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Novo Nordisk Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119-6100
- Novo Nordisk Investigational Site
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Novo Nordisk Investigational Site
-
Sea Girt, New Jersey, United States, 08750
- Novo Nordisk Investigational Site
-
-
North Carolina
-
Asheville, North Carolina, United States, 28803
- Novo Nordisk Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Novo Nordisk Investigational Site
-
-
Texas
-
Dallas, Texas, United States, 75235
- Novo Nordisk Investigational Site
-
Dallas, Texas, United States, 75390-8858
- Novo Nordisk Investigational Site
-
Houston, Texas, United States, 77030
- Novo Nordisk Investigational Site
-
San Antonio, Texas, United States, 78229
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Type 1 diabetes for at least 12 months
- Current treatment with basal-bolus insulin regimen for more than or equal to 3 months
- HbA1c less than or equal to 11.0%
Exclusion Criteria:
- Proliferative retinopathy or maculopathy
- Recurrent major hypoglycaemia
- Impaired hepatic or renal function
- Cardiac problems or uncontrolled hypertension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
HbA1c
Time Frame: after 1 year trial period
|
after 1 year trial period
|
Secondary Outcome Measures
Outcome Measure |
---|
Adverse events
|
Blood glucose
|
Body weight
|
Hypoglycemia
|
Insulin Treatment Satisfaction
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2004
Primary Completion (Actual)
December 1, 2005
Study Completion (Actual)
December 1, 2005
Study Registration Dates
First Submitted
October 29, 2004
First Submitted That Met QC Criteria
October 29, 2004
First Posted (Estimate)
November 1, 2004
Study Record Updates
Last Update Posted (Estimate)
January 27, 2017
Last Update Submitted That Met QC Criteria
January 26, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN304-1430
- 2004-000086-35 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on insulin aspart
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1Germany
-
Novo Nordisk A/SCompletedHealthy | DiabetesGermany
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Austria
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesBelgium, Luxembourg
-
Medical University of GrazCompleted
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Denmark
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesJapan
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany